Matthias Preusser
Universitaetsklinikum Wien - AKH uniklinieken, Vienna, Austria. · Medical University of Vienna, Vienna General Hospital (Austria) · Medical University of Vienna, Vienna General Hospital, Vienna, Austria
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matthias Preusser as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:55 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06809322 · Vorasidenib Maintenance for IDH Mutant AstrocytomaEuropean Organisation for Research and Treatment of Cancer - EORTC · recruiting · IDH-mutant Grade 2 or 3 Astrocytoma · study chair
- Ph2NCT06676917 · Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain MetastasesMedSIR · withdrawn · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT06048718 · T-DXd Therapy for HER2-low Breast Cancer Patients With Brain MetastasesMedSIR · active not recruiting · Breast Cancer, Metastatic Breast Cancer · principal investigator
- Ph3NCT05904119 · Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III StudyEuropean Organisation for Research and Treatment of Cancer - EORTC · recruiting · First Progression of Glioblastoma · principal investigator
- Ph2NCT05865990 · HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal DiseaseMedSIR · completed · Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult · principal investigator
- Ph2NCT02779101 · Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)Prof. Dr. Matthias Preusser · unknown · Primary Central Nervous System Lymphoma · principal investigator
- Ph2NCT02234050 · Trabectedin for Recurrent Grade II/III MeningiomaEuropean Organisation for Research and Treatment of Cancer - EORTC · completed · Recurrent High Grade Meningioma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:55 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.Nat Med · 2022347 citationsRCR 23.1
- 188 citationsRCR 10.5
- 182 citationsRCR 8.3
- Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.Neuro Oncol · 2023143 citationsRCR 13.8
- Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.Neuro Oncol · 201974 citationsRCR 3.8
- Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).Neuro Oncol · 202274 citationsRCR 6.3
- Neurocognitive training in patients with high-grade glioma: a pilot study.J Neurooncol · 201067 citationsRCR 2.2
- A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).Neuro Oncol · 201467 citationsRCR 2.1
- Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.Neuro Oncol · 202466 citationsRCR 7.2
- Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.Neuro Oncol · 202451 citationsRCR 6.9